P1015: DURATION OF TREATMENT AND REDUCTION IN SERUM TRYPTASE LEVELS IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY

P1015: DURATION OF TREATMENT AND REDUCTION IN SERUM TRYPTASE LEVELS IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY

Bibliographic Details
Main Authors:	A. Reiter, J. Gotlib, I. Álvarez-Twose, D. H. Radia, J. Luebke, P. J. Bobbili, A. Wang, C. Norregaard, S. Dimitrijević, E. Sullivan, M. Louie-Gao, J. Schwaab, I. A. Galinsky, C. Perkins, W. R. Sperr, P. Sriskandarajah, A. Chin, S. R. Sendhil, M. S. Duh, P. Valent, D. J. DeAngelo
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000846928.64504.71

Similar Items

P1014: OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR CLADRIBINE
by: A. Reiter, et al.
Published: (2022-06-01)

P1013: OVERALL SURVIVAL IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGIC NEOPLASM TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY
by: A. Reiter, et al.
Published: (2022-06-01)

P1027: RESPONSES TO AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS: HISTOPATHOLOGIC ANALYSES FROM EXPLORER AND PATHFINDER CLINICAL STUDIES
by: T. George, et al.
Published: (2022-06-01)

Clonal dynamics of aggressive systemic mastocytosis on avapritinib therapy
by: Xiaomeng Huang, et al.
Published: (2024-10-01)

PB2059: SUCCESSFUL OUTCOME OF A PATIENT WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED WITH AZACYTIDINE AND AVAPRITINIB: A CASE REPORT
by: C. Saha, et al.
Published: (2022-06-01)

P1023: AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM): EFFICACY AND SAFETY ANALYSES FROM THE PHASE 2 PATHFINDER STUDY WITH 2-YEAR FOLLOW-UP
by: Jason Gotlib, et al.
Published: (2023-08-01)

A case of indolent systemic mastocytosis responding to treatment with Avapritinib
by: Terrence Sun, et al.
Published: (2024-02-01)

P1017: REDUCTIONS IN INDOLENT SYSTEMIC MASTOCYTOSIS BIOMARKER BURDEN WITH AVAPRITINIB IN THE REGISTRATIONAL, DOUBLE-BLIND PLACEBO-CONTROLLED PIONEER TRIAL
by: Jason Gotlib, et al.
Published: (2023-08-01)

Avapritinib treatment of aggressive systemic mastocytosis with a novel KIT exon 17 mutation
by: Lyndsey Sandow, et al.
Published: (2024-01-01)

Venom immunotherapy in indolent systemic mastocytosis with high serum tryptase level
by: Ali Selcuk, et al.
Published: (2021-06-01)

Assessment of skin manifestations under mastocytosis in adults and their associations with symptoms, level of tryptase and subtype of the disease
by: N. P. Teplyuk, et al.
Published: (2021-06-01)

The clinical experience of compassionate use program for avapritinib: implications for drug positioning in the therapeutic scenario of systemic mastocytosis
by: Francesco Mannelli, et al.
Published: (2023-10-01)

A UK Survey Examining the Experience of Adults With Mastocytosis Receiving COVID-19 Vaccination
by: Priya Sriskandarajah, et al.
Published: (2021-11-01)

Avapritinib-based SAR studies unveil a binding pocket in KIT and PDGFRA
by: A. Teuber, et al.
Published: (2024-01-01)

Photosensitivity From Avapritinib: Pharamacovigilance Analysis
by: Ajit Venkatakrishnan, et al.
Published: (2022-08-01)

Systemic Mastocytosis: Following the Tyrosine Kinase Inhibition Roadmap
by: Miguel Piris-Villaespesa, et al.
Published: (2020-04-01)

Indolent systemic mastocytosis without skin involvement vs. isolated bone marrow mastocytosis
by: Luis Escribano, et al.
Published: (2011-04-01)

Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice
by: Celalettin Ustun, et al.
Published: (2016-10-01)

Cognitive, neuropsychiatric and neurological alterations in mastocytosis: A systematic review
by: Elena Sagües‐Sesé, et al.
Published: (2023-12-01)

Recent Advances in the Therapeutic Management of Advanced Systemic Mastocytosis
by: Scott Veitch, et al.
Published: (2023-12-01)

Variability of PD-L1 expression in mastocytosis
by: Ellen W. Hatch, et al.
Published: (2018-02-01)

Tryptase and tumor angiogenesis
by: Domenico Ribatti
Published: (2024-12-01)

Banihosnavie empire from emergence to decline (941 â 1015)
by: N.A Dehnavi
Published: (2014-08-01)

KIT D816V and the cytokine storm in mastocytosis: production and role of interleukin-6
by: Peter Valent
Published: (2020-01-01)

Dengue virus – elicited tryptase induces endothelial permeability and shock
by: Rathore, Abhay P. S., et al.
Published: (2020)

Application of the Montreal Classification for Crohn’s Disease to a Single Clinician Database of 1015 Patients
by: Hugh J Freeman
Published: (2007-01-01)

First Description of the Clinical Activity of Avapritinib in Sporadic Mesenteric Desmoid Tumor
by: Rebecca Ganzon, et al.
Published: (2024-01-01)

Tryptase in children in the practice of an allergist
by: D. Sh. Macharadze
Published: (2023-03-01)

Mast cell tryptase and asthma
by: M-Q. Zhang, et al.
Published: (1997-01-01)

P1038: CLINICOPATHOLOGIC AND MOLECULAR CORRELATES OF ORGAN DAMAGE ACROSS THE SPECTRUM OF ADVANCED SYSTEMIC MASTOCYTOSIS
by: E. Liang, et al.
Published: (2022-06-01)

Mastocytosis
by: Sandra Nora González-Díaz, et al.
Published: (2015-02-01)

Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis
by: Georg Greiner, et al.
Published: (2020-02-01)

Aggressive systemic mastocytosis with sarcoma-like growth in the skeleton, leukemic progression, and partial loss of mast cell differentiation antigens
by: M.T. Krauth, et al.
Published: (2007-12-01)

An elusive case of systemic mastocytosis
by: Lee JK, et al.
Published: (2010-05-01)

Cutaneous types of mastocytosis in paediatry. Case report of maculopapular cutaneous mastocytosis in an infant
by: Olga B. Tamrazova, et al.
Published: (2020-01-01)

Mast cells and tryptase. Modern aspects
by: D. Sh. Macharadze
Published: (2021-12-01)

Relevance of histamine and tryptase concentrations in nasal secretions after nasal challenges with phosphate buffered saline and allergen
by: D. Wang, et al.
Published: (1995-01-01)

Skin and bones: systemic mastocytosis and bone
by: Mawson Wang, et al.
Published: (2023-05-01)

Avapritinib treatment of KIT D816V-mutant atypical chronic myeloid leukemia
by: Lyndsey Sandow, et al.
Published: (2023-01-01)

Mastocytosis in Pregnancy
by: Ilknur Col Madendag, et al.
Published: (2010-06-01)